Journal of Clinical Oncology
Articles in this Issue
A phase 1/2 study of revumenib in patients (pts) with advanced colorectal cancer (CRC) and other solid tumors.
130 Background: Aberrant activation of the Wnt/β-catenin signaling pathway contributes to solid tumor development, particu...
A meta-analysis of immunotherapy combinations for first-line treatment in hepatocellular carcinoma: Efficacy and safety outcomes.
577 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Immune checkpoint inhibitors (ICPI...
First-line chemotherapy in metastatic colorectal cancer: Comparative outcomes from a resource-limited setting.
68 Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide and ranks among the...
Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC).
189 Background: Aspirin use is established as adjuvant therapy for PIK3CA mutant (...
KEYSTEP-008: Pembrolizumab (pembro)-based combinations for microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
137 Background: The open-label, phase 2 KEYSTEP-008 study (NCT04895722) evaluated pembro-based combinations vs pembro in p...
Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.
564 Background: Neoadjuvant treatment is considered to effectively reduce the postoperative recurrence rate of resectable...
T-CORE2401 trial: A randomized phase II trial of mFOLFOX6 plus cetuximab versus mFOLFOX6 plus bevacizumab as first-line treatment for right-sided, <i>RAS</i> / <i>BRAF</i> wild-type, low-methylated metastatic colon cancer.
TPS280 Background: For metastatic colorectal cancer, clinical benefit of anti-EGFR monoclonal antibody (mAb) has been limi...
Survival and treatment trends in BRCA-mutated metastatic pancreatic adenocarcinoma.
769 Background: Patients with metastatic pancreatic cancer and pathogenic germline BRCA mutations have improved survival w...
Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: A single-center, real-world study in Mexico.
72 Background: Total neoadjuvant therapy (TNT) has emerged as a pivotal treatment approach for locally advanced rectal can...
Pooled analysis of individual patient data (IPD) from clinical trials of trifluridine/tipiracil (FTD/TPI) and bevacizumab (BEV) for metastatic colorectal cancer (mCRC).
152 Background: The combination therapy of FTD/TPI plus BEV showed a survival benefit in the third- or later-line treatmen...
Prevalence of clonal hematopoiesis of indeterminate potential across different systemic cancer therapies in gastrointestinal malignancies: An analysis from the All of Us registry.
828 Background: Clonal hematopoiesis of indeterminate potential (CHIP) refers to the presence of somatic mutations in hema...
Continuous, maintenance or intermittent first line (1L) therapy for advanced pancreatic cancer (aPC): MI-OPTS-1 study.
731 Background: 1L therapy for patients (pts) with aPC includes FOLFIRINOX, gemcitabine/ nab-paclitaxel (GnP), or NALIRIFO...
Characterizing the clinical presentation of early-onset colorectal cancer: Constipation as a novel marker.
35 Background: While colorectal cancer (CRC) incidence overall is declining, early-onset CRC (EOCRC, diagnosed before age...
A real-world comparison of overall survival (OS) in deficient mismatch repair/microsatellite instability high (dMMR) versus proficient mismatch repair/microsatellite instability low (pMMR) disease in gastroesophageal (GE) cancer patients (pts).
400 Background: Immune checkpoint inhibitors (ICIs) have drastically changed the landscape of treatment in GE cancer. The...
Randomized phase II trial evaluating the efficacy of zolbetuximab in the second-line for claudin18.2 positive advanced gastric/EGJ cancer patients previously treated with zolbetuximab and platinum-based chemotherapy (ZELDA trial).
TPS470 Background: Gastric and gastroesophageal adenocarcinomas (GC/GEJC) are common cancers with, particularly in Asia, a...
GLP-1 receptor agonists and pancreatic cancer risk: A meta-analysis of real-world and trial evidence.
712 Background: Pancreatic cancer is one of the most lethal gastrointestinal malignancies, with obesity and smoking as key...
Impact of adjuvant mFOLFOX6 on imaging diagnosis after hepatectomy for colorectal liver metastasis: A supplemental analysis of JCOG0603.
120 Background: Recent studies have reported that relapse-free survival is not a reliable surrogate endpoint for overall s...
Proposal of a novel pND-based staging system for locoregional gastric neuroendocrine carcinoma: A multicenter retrospective study.
624 Background: Gastric neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy lacking a disease-specific staging...
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial.
545 Background: Zanidatamab is a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody that re...
Subgroup analyses from the phase 3 PANOVA-3 trial of tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in locally advanced pancreatic adenocarcinoma: Efficacy and safety by sex, age, and body mass index (BMI).
707 Background: Due to insufficient data, therapy for unresectable, locally advanced pancreatic adenocarcinoma (LAPAC) is...
Genomic landscape and clinical correlates of ALK fusions in colorectal cancer.
205 Background: Anaplastic lymphoma kinase (ALK) fusions are well‐established therapy targets in non‐small cell lung cance...
Diagnostic accuracy of circulating tumor DNA for early detection of colorectal cancer: A systematic review and meta-analysis.
34 Background: Blood-based circulating tumor DNA (ctDNA) assays represent a promising non-invasive method for colorectal c...
Short-term outcomes of induction FLOT plus nivolumab for unresectable locally advanced esophageal squamous cell carcinoma in cisplatin-unfit patients.
319 Background: Definitive chemoradiotherapy (dCRT) remains the standard of care for unresectable locally advanced esophag...
Comparative outcomes of pancreatic versus duodenal adenocarcinoma: A National Cancer Database analysis.
686 Background: Pancreatic and duodenal adenocarcinomas share anatomic proximity but may differ in tumor biology, treatmen...
In-hospital outcomes of splanchnic vein thrombosis in patients with gastrointestinal malignancies.
853 Background: Splanchnic vein thrombosis (SVT) is an uncommon but important complication of GI malignancies. Evidence on...